Lyophilized CJC-1295 DAC represents a specialized growth hormone-releasing hormone (GHRH) derivative optimized for extended biochemical stability in preclinical research. Designed with a proprietary Drug Affinity Complex, this modified peptide enables researchers to study sustained somatotroph activation and downstream anabolic signaling pathways. PX1 Research provides analytical-grade formulations supported by lot-specific mass spectrometry and HPLC purity verification.
Lyophilized CJC-1295 DAC represents a specialized growth hormone-releasing hormone (GHRH) derivative optimized for extended biochemical stability in preclinical research. Designed with a proprietary Drug Affinity Complex, this modified peptide enables researchers to study sustained somatotroph activation and downstream anabolic signaling pathways. PX1 Research provides analytical-grade formulations supported by lot-specific mass spectrometry and HPLC purity verification.
Lyophilized CJC-1295 DAC is a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog featuring a Drug Affinity Complex (DAC) modification. Freeze-dried for long-term molecular stability, it covalently binds to endogenous plasma albumin in laboratory assays, extending half-life to enable sustained growth hormone (GH) and insulin-like growth factor 1 (IGF-1) research.
Structurally, the base sequence is a modified version of growth hormone-releasing factor 1-29 (GRF 1-29), incorporating amino acid substitutions at positions 2, 8, 15, and 27. These specific modifications enhance resistance to enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-IV). The defining feature of this variant is the attachment of a maleimidopropionic acid linker to the lysine residue at position 27, constituting the Drug Affinity Complex. Investigators seeking pure reference material can review technical specifications on our CJC-1295 DAC product page.
At the cellular level, CJC-1295 DAC functions as a potent agonist at the GHRH receptor located on somatotroph cells in the anterior pituitary gland. Upon binding, the peptide triggers a conformational change that activates the G s-alpha protein subunit. This subunit stimulates adenylyl cyclase, driving the intracellular conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP).
Elevated intracellular cAMP levels activate protein kinase A (PKA), which subsequently phosphorylates specific transcription factors, such as cAMP response element-binding protein (CREB). In vitro assays demonstrate that this cascade leads to both transcription of the GH gene and exocytosis of stored growth hormone vesicles. Because of its structural resistance to cleavage, CJC-1295 DAC maintains receptor engagement over extended periods compared to native baseline GHRH, as documented across studies in the PX1 research library.
The primary biochemical limitation of native GHRH(1-29) is its rapid degradation in systemic circulation, resulting in an in vivo half-life of less than twelve minutes. The incorporation of the Drug Affinity Complex (DAC) fundamentally alters these pharmacodynamics by permitting bioconjugation to circulating serum proteins.
Specifically, the maleimide moiety of the DAC linker forms a stable, covalent thioether bond with the free thiol group on Cys34 of serum albumin. Because albumin has a natural circulatory half-life of approximately 19 to 20 days in mammalian models, the conjugated peptide is protected from renal filtration and enzymatic cleavage. Preclinical models demonstrate that this conjugation extends the biological half-life of CJC-1295 to several days, transforming a short-acting secretagogue into a continuous driver of baseline GH and IGF-1 secretion.
Preclinical investigations utilizing rodent and non-human primate models indicate that CJC-1295 DAC alters typical endocrine profiles. While native GHRH induces discrete, rapid pulsatile release of growth hormone, CJC-1295 DAC generates a sustained, baseline elevation of GH without completely abolishing natural pulsatility. This physiological pattern leads to continuous transcription and release of insulin-like growth factor 1 (IGF-1) from hepatic tissue.
Animal study data indicate that sustained elevation of the GH/IGF-1 axis via CJC-1295 DAC enhances muscle protein synthesis, accelerates cellular turnover in connective tissue models, and promotes nitrogen retention. In research evaluating cartilage regeneration and wound healing parameters, sustained IGF-1 expression induced by CJC-1295 DAC has been associated with increased extracellular matrix production and cellular proliferation.
Evaluating secretagogue kinetics requires comparing CJC-1295 DAC against non-conjugated GHRH analogs and growth hormone secretagogue receptor (GHSR) agonists. While CJC-1295 DAC provides multi-day elevation of GH and IGF-1 due to albumin binding, CJC-1295 No DAC lacks the reactive linker and exhibits a dramatically shorter half-life (30–30 minutes), making it better suited for studying discrete GH pulses.
When compared to shorter-acting GHRH derivatives like Sermorelin, CJC-1295 DAC exhibits significantly higher metabolic stability. Furthermore, researchers frequently examine synergistic pathways by pairing GHRH analogs with ghrelin mimetics such as Ipamorelin. Whereas GHRH analogs activate the adenylyl cyclase pathway via GHRH receptors, GHSR agonists operate through the phospholipase C pathway, resulting in amplified GH release when co-administered in in vitro laboratory protocols. A comprehensive selection of these targets is available in our catalog of research peptides.
Lyophilization, or freeze-drying, is a critical preservation process for peptide compounds sensitive to hydrolytic degradation. The process involves freezing the aqueous peptide solution, followed by primary drying via sublimation to remove ice crystals under vacuum, and secondary drying to remove bound moisture molecules.
The resulting lyophilized cake presents low moisture content (typically < 1%) and a porous structure that dissolves rapidly upon reconstitution. In its freeze-dried state, CJC-1295 DAC exhibits superior thermal stability compared to liquid solutions, preventing peptide aggregation, oxidation of methionine residues, and peptide bond hydrolysis during transport and long-term storage.
Achieving consistent assay results requires proper reconstitution techniques to preserve secondary peptide structure. Researchers should allow the vial of lyophilized CJC-1295 DAC to reach room temperature before introducing diluents, minimizing moisture condensation on the internal cake.
Reconstitution is typically performed using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution depending on the specific sensitivity of the cell culture or assay matrix. The diluent should be introduced gently down the inner glass wall of the vial rather than sprayed directly onto the peptide cake. Gentle swirling or rotation of the vial is recommended; vigorous agitation or vortexing must be avoided, as shear forces can induce peptide denaturation or aggregation.
Reliable preclinical research depends entirely on compound purity and lot-to-lot consistency. Unrefined or degraded peptides can yield false-positive cellular responses or toxicity artifacts in culture. PX1 Research enforces strict quality control standards for every lot of lyophilized CJC-1295 DAC.
Analytical verification involves Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish chemical purity (>98%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular mass. Additionally, Limulus Amebocyte Lysate (LAL) testing is conducted to verify endotoxin levels remain below strictly defined thresholds (<0.05 EU/mg), ensuring compatibility with sensitive biological assays. Certificates of Analysis (COAs) containing full analytical spectra are provided for every lot.
To prevent degradation of lyophilized CJC-1295 DAC, unopened vials should be stored in a dry, dark environment at -20°C for short-to-medium term storage, or at -80°C for multi-year preservation. Vials must be protected from direct light exposure to avoid photo-oxidation.
Once reconstituted into liquid solution, the peptide's chemical stability decreases significantly. Reconstituted aliquots should be held at 2°C to 8°C and utilized within a defined experimental window (typically 14 to 28 days depending on the bacteriostatic agent). Repeated freeze-thaw cycles of reconstituted liquid must be avoided, as the physical stress of ice crystal formation causes peptide backbone cleavage and irreversible aggregation.
Institutional laboratories requiring high-volume or ongoing supplies of lyophilized CJC-1295 DAC must partner with reputable domestic vendors capable of guaranteeing lot traceability and strict compliance with analytical standards. For specialized procurement setups, facilities can access dedicated services through our wholesale laboratory accounts.
PX1 Research manufactures peptides in USA-based, GMP-compliant facilities utilizing ISO 17025 accredited laboratory testing protocols. All orders ship directly from fulfillment centers in California and Arizona, offering same-day dispatch Monday through Friday to ensure fast delivery and minimal transit stress on temperature-sensitive research materials.
What is the primary structural difference between CJC-1295 DAC and CJC-1295 No DAC?
The primary structural difference is the presence of the Drug Affinity Complex (DAC) linker (maleimidopropionic acid) bound to the lysine residue at position 27 on CJC-1295 DAC. This modification allows the peptide to covalently bind to serum albumin, extending its biological half-life significantly compared to CJC-1295 No DAC.
How should lyophilized CJC-1295 DAC be stored upon receipt?
Unopened, lyophilized CJC-1295 DAC should be stored in a freezer at -20°C to -80°C in a dry, dark environment. Stored at these temperatures, the freeze-dried peptide remains stable for extended periods.
Which reconstituting solution is recommended for in vitro research assays?
Reconstitution is typically carried out using sterile bacteriostatic water (0.9% benzyl alcohol) for multi-use laboratory applications or sterile 0.9% saline for sensitive cell culture environments where preservative interference must be minimized.
What purity level is guaranteed for PX1 Research CJC-1295 DAC?
PX1 Research guarantees a minimum purity of 98% for CJC-1295 DAC, verified via Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS).
Why is endotoxin testing critical for research-grade peptides?
Endotoxins (lipopolysaccharides) can trigger immune responses or cellular toxicity in cell cultures and animal models, confounding experimental results. Testing via LAL assay ensures endotoxin levels are below strict safety parameters (<0.05 EU/mg).
What receptor target does CJC-1295 DAC interact with in biological models?
CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotrophs.
Can CJC-1295 DAC be freeze-thawed repeatedly after reconstitution?
No. Repeated freeze-thaw cycles cause mechanical stress that damages the peptide structure, leading to precipitation and loss of bioactivity. Reconstituted solution should be divided into single-use aliquots if frozen storage is necessary.
Where is PX1 Research peptide material manufactured and dispatched from?
All PX1 Research compounds are synthesized in USA-based GMP-compliant facilities and shipped directly from fulfillment hubs located in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.